Sign in
CMRA Stock Price, Chart, Stats & News
Comera Life Sciences Holdings, Inc.
Save
Comera Life Sciences Holdings, Inc. (CMRA) does not currently pay a dividend.
6,148
Market cap
–
Current P/E
–
Forward P/E
CMRA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 66.77% |
Operating margin | -1890.69% |
Pretax margin | -2843.79% |
Net margin | -2843.79% |
Effective tax rate | – |
ROA | -483.06% |
ROE | 47452.88% |
D/E | -0.12x |
Interest coverage ratio | -587.02x |
CMRA valuation
P/E | – |
P/S | 0.00x |
P/B | -0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | -0.00x |
EV multiple | 0.02x |
About
Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms. Currently, the company is progressing two main product candidates: CLS-001, an early-stage "biobetter" designed to treat inflammatory bowel conditions like Crohn's and Ulcerative Colitis, and CLS-002, another preclinical biobetter aimed at diverse oncology indications.
Similar securities
Based on sector and market capitalization
Report issue